A Phase II, Open (Partially Double-blind), Randomized, Controlled Dose-range Study to Evaluate the Immunogenicity, Reactogenicity and Safety of Investigational Vaccination Regimens Versus MENINGITEC or MENCEVAX ACWY When Given as One Dose to Children Aged 12 to 14 Months and 3 to 5 Years Old.

Trial Profile

A Phase II, Open (Partially Double-blind), Randomized, Controlled Dose-range Study to Evaluate the Immunogenicity, Reactogenicity and Safety of Investigational Vaccination Regimens Versus MENINGITEC or MENCEVAX ACWY When Given as One Dose to Children Aged 12 to 14 Months and 3 to 5 Years Old.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2015

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; Meningococcal vaccine group C conjugate; Meningococcal vaccine groups A C Y W-135 polysaccharide
  • Indications Meningitis; Meningococcal infections; Various toxicities
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 04 Oct 2011 Official Title amended as reported by ClinicalTrials.gov.
    • 16 Dec 2009 Results were published in Vaccine.
    • 07 Mar 2008 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top